Best Healthcare Equipment Companies To Watch In Right Now

In the past, one of the key advantages of buying a Microsoft (NASDAQ: MSFT  ) Windows PC was for its backwards compatibility with applications designed for previous versions of Windows. For the end user, it meant you wouldn't have to repurchase all of your software when upgrading to a new Windows PC. Nowadays, the rise of cloud computing and Web applications has changed the collective mind-set that backwards compatibility is a must-have feature.

A new world
Gartner believes that the public cloud computing industry will grow by 18.5% to become a $131 billion worldwide industry this year. The software-as-a-service market, which consists of Web-based applications, is expected to become a $19.3 billion sub-industry. For the end user, the beauty of the cloud is that your applications will often work on a host of different devices, meaning you have more flexibility to be operating system-agnostic. In this context, the operating system becomes less important and the focus becomes geared toward the user experience.

Best Healthcare Equipment Companies To Watch In Right Now: Givaudan SA (GIVN)

Givaudan SA is a Switzerland-based holding company engaged in the fragrance and flavor industry. The Company has two business divisions: Fragrances and Flavors. The Fragrances business segment comprises the manufacture and sale of fragrances into three global business units: Fine Fragrances, comprising signature fragrances and line extensions, Consumer Products, comprising fabric and personal care, hair and skin care, household and air care, as well as oral care, and Fragrance Ingredients. The Flavors business division comprises the manufacture and sale of flavors into four business units: Beverages, comprising flavors for soft drinks, fruit juices and instant beverages; Dairy, comprising ice cream, yoghurt, desserts and yellow fats; Savory, covering soups and sauces, among others; and Confectionery. The Company is also engaged in research and development activities, which comprises the development of a palette of perfumery raw materials, both synthetic and natural. Advisors' Opinion:

• [By Celeste Perri]

  Nestle SA (NESN) is selling Givaudan (GIVN) SA shares worth $1.27 billion at yesterday�� closing price to institutional investors, winding down its stake in the world�� largest flavorings maker.

Best Healthcare Equipment Companies To Watch In Right Now: Xoom Corp (XOOM)

Xoom Corporation (Xoom), incorporated on October 10, 2012, is engaged in online international money transfer service. Its customers use Xoom to send money to family and friends in 30 countries. The Company generates revenue from transaction fees charged to customers and from foreign exchange spreads on transactions where the payout currency is other than United States dollars. In February 2014, Xoom Corp acquired BlueKite, LTD, a technology company that develops solutions and applications.

The Company�� solutions are designed to offer customers a convenient, fast and cost-effective way to send money to family and friends at any time, from any Internet-enabled location. The Company�� solutions include Origination, Funding, Disbursement and Transaction Processing.

Advisors' Opinion:

• [By John Udovich]

  Small cap money transfer stock Euronet Worldwide, Inc (NASDAQ: EEFT) and Wal-Mart Stores, Inc (NYSE: WMT) have announced an exclusive money transfer service called "Walmart-2-Walmart,��meaning its time to take a closer look at the stock along with the performance of peers like Moneygram International Inc (NASDAQ: MGI), Xoom Corp (NASDAQ: XOOM) and The Western Union Company (NYSE: WU) which fell 17.68%, 4.32% and 4.98%, respectively.

• [By Alex Planes]

  What: Shares of Xoom (NASDAQ: XOOM  ) have rocketed higher today and are now sitting 15% above yesterday's close after obliterating analyst estimates with strong earnings.

• [By John Kell]

  Xoom Corp.(XOOM) swung to a fourth-quarter profit as the international money-transfer provider reported a jump in revenue. But the company’s full-year earnings outlook fell short of Wall Street’s expectations. Shares dropped 13% to $24.46 premarket.

5 Best Growth Stocks To Buy Right Now: CECO Environmental Corp.(CECE)

CECO Environmental Corp. provides air-pollution control technology products and services worldwide. The company offers engineered equipment, cyclones, scrubbers, dampers, diverters, regenerative thermal oxidizers, component parts, and monitoring and managing services. Its Engineered Equipment Technology and Parts Group segment provides air handling equipment and systems for filtering, cooling, heating, and capturing emissions in the metal industries; systems for corrosion protection, fugitive emissions control, evaporative cooling, and other ventilation and air handling applications; and fume exhaust systems that provide control of oil mist and fumes, as well as remove liquid particles and vapor phase emissions from rolling mill, machining, and other oil mist generating processes. This segment also markets a strip cooler under the JET*STAR name designed to cool metal strip coatings. The company?s Contracting/Services Group segment offers oil mist collection, dust collecti on, industrial exhaust, chip collection, make-up air, and automotive spray booth systems, as well as industrial and process piping, and other industrial sheet metal works. This segment also engages in fabricating parts, engineered subassemblies, and customized products for air pollution and non-air pollution systems from sheet, plate, and structurals. Its Component Parts Group segment manufactures and markets component parts for industrial air systems to contractors, distributors, and dealers. The company markets its products and services under the Kirk & Blum, CECO Filters, Busch International, CECO Abatement Systems, KB Duct, Effox, Fisher-Klosterman, Buell, A.V.C., FKI, and Flextor names. It serves aerospace, brick, cement, steel, ceramics, metalworking, printing, paper, food, foundries, utilities, metal plating, woodworking, chemicals, glass, automotive, ethanol, pharmaceuticals, and refining industries. CECO Environmental Corp. was founded in 1966 and is headquartered i n Cincinnati, Ohio.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on CECO Environmental (Nasdaq: CECE  ) , whose recent revenue and earnings are plotted below.

Best Healthcare Equipment Companies To Watch In Right Now: Huntington Ingalls Industries Inc. (HII)

Huntington Ingalls Industries, Inc. designs, builds, overhauls, and repairs ships primarily for the U.S. Navy and Coast Guard. It offers nuclear-powered ships, such as aircraft carriers and submarines; and non-nuclear ships, including surface combatants, expeditionary warfare/amphibious assault, coastal defense surface ships, and national security cutters, as well as engages in the refueling and overhaul, and inactivation of nuclear-powered ships. The company also operates as a full-service systems provider for the design, engineering, construction, and life cycle support of major programs for surface ships; and a provider of fleet support and maintenance services for the U.S. Navy. In addition, it provides a range of support services, including fabrication, construction, equipment, and technical services, as well as product sales to commercial nuclear power plants, fossil power plants, and other industrial facilities, as well as government customers. The company is based in Newport News, Virginia.

Advisors' Opinion:

• [By Rich Smith]

  The contracts in question awarded to major martial shipbuilders Huntington Ingalls (NYSE: HII  ) and Bath Iron Works (the General Dynamics (NYSE: GD  ) subsidiary), respectively, are worth a combined $6.2 billion and commission the two defense contractors to build a total of nine Arleigh Burke-class (DDG 51) guided missile destroyers.

• [By Rich Smith]

  Shipbuilder Huntington Ingalls Industries (NYSE: HII  ) will build a sixth National Security Cutter (NSC) for the U.S. Coast Guard, Huntington announced Wednesday.

Best Healthcare Equipment Companies To Watch In Right Now: Cyberonics Inc (CYBX)

Cyberonics, Inc. (Cyberonics), incorporated in 1987, is a medical device company. The Company is engaged in the design, development, sales and marketing of implantable medical devices that provide a neuromodulation therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression (TRD) and other device solutions for the management of epilepsy.VNS Therapy System includes an implantable pulse generator to provide stimulation to the vagus nerve; a lead that connects the generator to the vagus nerve; equipment to assist with implantation surgery; equipment to assist with setting the stimulation parameters for each patient; instruction manuals, and magnets to suspend or induce stimulation manually. The VNS Therapy pulse generator and lead are surgically implanted into patients generally during an outpatient procedure. The VNS Therapy System consists of a pulse generator, a bipolar lead, a programming wand and software and a tunneling tool.

The United States Food and Drug Administration (FDA) approved the Company's VNS Therapy System in July 1997 for use as an adjunctive therapy in epilepsy patients over 12 years of age for reducing the frequency of partial onset seizures that are refractory or resistant to antiepileptic drugs. Regulatory bodies in Canada, the European Economic Area, certain countries in Eastern Europe, Russia, South America, Africa, Australia and certain countries in Asia, including Japan, China and Taiwan, have approved the VNS Therapy System for the treatment of epilepsy, many without age restrictions or seizure-type limitations. In July 2005, the FDA approved the Company's VNS Therapy System for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a depressive episode and have not had an adequate response to four or more adequate anti-depressant treatments. Regulatory bodies in the European Economic Area, Canada and Israel have approv! ed the Company's VNS Therapy System for the treatment of chronic or recurrent depression in patients who are in a treatment-resistant or treatment-intolerant depressive episode without age restrictions.

In February 2011, the Company announced FDA approval of its fifth generation generator, the AspireHC generator. In August 2011, the Company announced that the Company discovered a hardware-related design issue with the AspireHC Model 105 and AspireSR (Seizure Response) Model 106 generators. In December 2011, the FDA approved the Company's re-designed AspireHC generator, and the Company resumed its limited commercial release of the generator in the United States.

Pulse Generator

The pulse generator is an implantable, programmable signal generator designed to be coupled with the bipolar lead to deliver mild electrical pulses to the vagus nerve. The pulse generator is a battery-powered device. Before or upon depletion of the battery, the pulse generator may be removed and a new generator implanted in a short, outpatient procedure. The Model 102 (Pulse), Model 102R (Pulse Duo ), Model 103 (Demipulse), Model 104 (Demipulse Duo) and Model 105 (AspireHC), are the VNS Therapy pulse generators the Company offers and are similar in design and manufactures to a cardiac pacemaker.

Bipolar Lead

The bipolar lead conducts the electrical signal from the pulse generator to the vagus nerve. The lead incorporates electrodes, which are self-sizing, minimizing mechanical trauma to the nerve. The lead's two electrodes and anchor tether wrap around the vagus nerve, and the connector end is tunneled subcutaneously to the upper chest area, where it attaches to the pulse generator. The Company offers three lead models in the United States. The leads are available in two inner spiral diameter sizes to ensure optimal electrode placement on different-sized nerves.

Programming Wand and Software

The Company's programming wand and software are us! ed to int! errogate the implanted pulse generator and to transmit programming information from a handheld computer to the pulse generator via an inductive coupling. Programming capabilities include modification of the pulse generator's programmable parameters (pulse width, amplitude and frequency and stimulation ON and OFF intervals) and storage and retrieval of telemetry data.

Tunneling Tool

The tunneling tool is a single use, sterile, disposable surgical tool designed to be used during surgical placement of the bipolar lead. The tool is used for subcutaneous tunneling of the lead between the nerve site in the neck and the pulse generator site in the upper chest area.

Accessory Pack

The accessory pack includes two resistor assemblies used to test the function of the device prior to implantation, the bipolar lead tie-downs and one hex screwdriver. The patient kit includes two magnets, one watch-style and one pager-style.

The Company competes with Medtronic, Inc., NeuroSigma Inc. and CerboMed GmbH.

Advisors' Opinion:

• [By Benjamin Shepherd]

  The rise of public health services, improvements in sanitation and access to clean drinking water have led to a huge improvement in human life expectancy, which has jumped from only about 30 years five centuries ago to more than 75 years in most industrialized countries today.
  
  Advances in medical science have also played a major role, such as the development of antibiotics to treat once deadly infections, surgical interventions to correct once fatal injuries and medications to treat chronic conditions.
  
  We have yet to reach the limit of human ingenuity and today the trend is towards harnessing technology to break the reliance on long-term medication usage to treat chronic conditions. One area where huge strides are being made in that direction is the treatment of epilepsy.
  
  Epilepsy is the fourth most common neurological disease in the world, affecting more than 9 million people in developed countries alone, and epileptics have a mortality rate more than 25 times higher than the general population. The costs associated with dealing with the disease run in excess of $13.5 billion in the US alone.
  
  The disease is typically treated using a drug regime that includes several pills a day, including anti-convulsants and sedatives which can have unpleasant side effects. Drug therapy is typically successful in controlling seizures in about 70 percent of patients, but about a third of those who don�� respond to medication find themselves undergoing surgery to essentially remove the area of the brain triggering the seizures.
  
  Cyberonics (NSDQ: CYBX) is making headway into an alternative treatment for the disease, called vagus nerve stimulation (VNS) therapy, which can reduce the number or even eliminate the need for the drugs epileptics depend upon and requires only minor surgery.
  
  During an outpatient procedure conducted under general anesthesia, two small incisions are made, one in the upper chest area and the other in the neck. At t

Best Healthcare Equipment Companies To Watch In Right Now: Gramercy Property Trust Inc (GPT)

Gramercy Property Trust Inc., formerly Gramercy Capital Corp., incorporated on April 1, 2004, is an integrated, self-managed real estate investment and asset management company. The Company�� principal business is to acquire and manage industrial and office properties, net leased to tenants in major markets throughout the United States. The Company owns, directly or in joint venture, a portfolio of 112 buildings totaling approximately 4.2 million square feet of office and 1.5 million square feet of industrial, net leased on a long-term basis to tenants, including Bank of America, Nestle Waters, Philips Electronics and others. In September 2013, it closed on five new acquisitions. In October 2013, it acquired an approximately 220,000 square foot food-grade cold storage and distribution facility located in Yuma, Arizona. In October 2013, the Company acquired approximately 120,350 square foot industrial facility in Austin, Texas. In November 2013, the Company announced the acquisition of six new properties.

In June 2013, the Company announced that it has closed on the acquisition of a build-to-suit of an approximately 120,0000 square foot industrial facility located in Hialeah, Gardens, Florida in the Miami Metropolitan Statistical Area. In July 2013, Gramercy Property Trust Inc closed on four acquisitions; a wholesale automotive auction facility in Dallas, Texas, an industrial cold storage facility in Southern New Jersey and two cross-dock truck terminals located in Houston, Texas and Orlando, Florida.

The Company's property management business, operating under the name Gramercy Asset Management, manages for third-parties commercial properties leased primarily to regulated financial institutions and affiliated users throughout the United States. The Company is actively acquiring industrial and office assets leased to companies in a variety of industries. The Company will primarily acquire long-term leased assets, but will acquire shorter leases with risk adjusted returns.

Advisors' Opinion:

• [By Chris DeMuth Jr.]

  This article is intended to update our readers on the progress on Gramercy Property Trust (GPT) through 2Q 2013. For background you may want to go back and read our previous articles. In this particular article, I will focus on 4 particular points:

Best Healthcare Equipment Companies To Watch In Right Now: FMC Corporation (FMC)

FMC Corporation, a chemical company, provides solutions, applications, and products for agricultural, consumer, and industrial markets. The company operates in three segments: Agricultural Products, Specialty Chemicals, and Industrial Chemicals. The Agricultural Products segment develops, markets, and sells a portfolio of crop protection, pest control, and lawn and garden products. It produces insecticides, herbicides, and fungicides to protect crops, including cotton, sugarcane, rice, corn, soybeans, cereals, fruits, and vegetables from insects and weed growth; and for non-agricultural applications, including pest control for home, garden, and other specialty markets, as well as for turf and roadside applications. The Specialty Chemicals segment focuses on food ingredients, pharmaceutical excipients, biomedical technologies, and lithium products. It produces microcrystalline cellulose that is used as drug dry tablet binder and disintegrant, and food ingredient; carrageena n, which is used as food ingredient for thickening and stabilizing; encapsulant for pharmaceutical and nutraceutical applications; alginates that are used as food ingredients, and for pharmaceutical excipient, wound care, orthopedic uses, and industrial uses; and lithium that is used in pharmaceuticals, polymers, batteries, greases and lubricants, air conditioning, and other industrial applications. The Industrial Chemicals segment produces inorganic materials, such as soda ash for glass, chemicals, and detergents; specialty peroxygens for pulp and paper, chemical processing, detergents, antimicrobial disinfectants, environmental applications, electronics, and polymers; and zeolites and silicates for detergents, car tires, pulp, and paper. It has operations in North America, Latin America, the Asia Pacific, Europe, the Middle East, and Africa. The company was founded in 1884 and is headquartered in Philadelphia, Pennsylvania.

Advisors' Opinion:

• [By Marc Courtenay]

  Some other names to consider as takeover targets would include FMC Technologies, Inc. (FTI), which provides technology solutions for the energy industry worldwide and hit a 52-week high on April 11th. Another less conspicuous target is the diversified chemical company FMC Corp. (FMC), which has a market cap of only $8 billion plus a forward PE of less than 13.

• [By Ben Levisohn]

  Timing of the transaction completion is mid 2015, following final approval of the BoD, receipt of favorable opinion on tax free status from IRS, shareholder approval, & all regulatory approvals. As a point of interest we have seen several announcements recently where an announcement of the split drives the stocks up 10% and quickly fades as timing sets in and market risk still exists. recent examples [Hertz (HTZ), FMC Corp (FMC), Agilent (A), Noble (NE), CBS (CBS)]. I would expect the stock to fade hard from these levels

• [By Rich Duprey]

  Just as Monsanto is enjoying a surge in sales of Roundup, pesticide makers are witnessing greater sales of pesticides to combat these superbugs. Revenues at Sygenta (NYSE: SYT  ) rose 1.5% to $4.2 billion, FMC's (NYSE: FMC  ) sales were 5% higher, and American Vanguard's (NYSE: AVD  ) surged 39% last quarter. The three companies account for three-quarters of all ground pesticides sold in the United States.

Best Healthcare Equipment Companies To Watch In Right Now: Interleukin Genetics Inc (ILIU.PK)

Interleukin Genetics, Inc., incorporated on March 28, 2000, is a personalized health company, which develops genetic tests to provide information to manage health and specific health risks. The Company�� business focuses on personalized health, by providing genetic tests with clinical value. Its tests are made available through marketing partners or directly to end users. The Company's primary business focus and strategy is to continue the Company's commercialization efforts with its PST genetic test. In addition, the Company plans to continue to develop and sells tests for its own business needs under the Inherent Health brand.

The Company's genetic tests that are being commercialized includes PST is a genetic test, which analyzes genetic variations associated with inflammation and identifies individuals who are at increased risk for more severe periodontal disease; Weight Management Genetic Test determines whether a low fat, low carbohydrate or balanced diet may normal or vigorous exercise, which is needed to lose existing body fat; Bone Health Genetic Test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis; Heart Health Genetic Test is designed to identify genetic predisposition to excess inflammation, which is a risk factor for heart attack, and Wellness Select Genetic Test allows buyers to purchase any combination of Inherent Health genetic tests at a discounted price. The Company is also focusing its genetic test development efforts on the development of an Osteoarthritis, or OA, genetic test to identify individuals at increased risk for severe OA.

Genetic Test for Risk of Periodontal Disease

PST is a genetic test that analyzes genetic variations associated with inflammation and identifies individuals who are at increased risk for more severe periodontal disease. The PST genetic test identifies specific polymorphisms (genetic variations) in genes that! regulate the production of interleukin cytokines.Interleukin-1 (IL-1) is well-established as one of the critical regulators of periodontal disease, and studies in non-human primates have shown that drugs specifically blocking IL-1 alone or IL-1 plus TNFa reduces tissue destruction even when the bacterial challenge is not reduced.

Inherent Health Brand of Genetic Tests

The Company's Weight Management Genetic Test helps take the guesswork out of finding an effective diet and exercise solution by revealing actionable steps to achieve weight goals based on genetics. The test provides new information beyond traditional assessments, so that nutritional intake and fitness routines can be tailored for improved, sustainable results. This test identifies five SNPs in four human genes: fatty acid binding protein 2 (FABP2); adrenergic receptor beta 2 (ADRB2 two variations); adrenergic receptor beta 3 (ADRB3); and peroxisome proliferator-activated receptor gamma (PPAR- ). These markers are involved in certain physiological pathways relating to body weight. Certain patterns of markers are associated with differential response to certain diet and exercise regimens.

The Company has conducted a number of studies that demonstrate a gene-diet interaction based on the multi-locus patterns . In the original study, 311 overweight/obese (body mass index, 27-40 kg/m2), nondiabetic, premenopausal, generally healthy women were randomly assigned for 12 months to either the Atkins-like ( low carbohydrate), Zone-like (low carbohydrate), LEARN-like (balanced), or Ornish-like (low fat) diets for the primary purpose of losing weight. The data collected in that study included dietary intake assessment (three unannounced 24-hour recalls for each time point administered by a dietitian and analyzed using NDS-R, University of Minnesota), anthropometric measures including weight, and related physiological variables, all collected at baseline, two, six, and 12 months.

Bone Health Genetic T! est

The Company's Bone Health Genetic Test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis. Although it typically starts later in life, early intervention can help prevent osteoporosis. Preventive measures can reduce the risk for bone loss and fractures, which in the case of vertebral fractures leads to a hunched over appearance. The test identifies a SNP in each of three genes involved in processes that affect bone; estrogen receptor alpha (ER1 Xba1), vitamin D receptor (VDR), and interleukin-1 (IL-1). Certain patterns of variations are associated with increased risk of spine fracture and/or low bone mineral density. The test can be used as an aid to making diet, exercise, and other lifestyle choices to maintain and improve bone health.

Nutritional Needs Genetics Test

The Company's Nutritional Needs Genetics Test is designed to identify DNA variations in genes crucial to B-vitamin metabolism and the ability to manage oxidative stress. Individuals with certain variations in these genes may be at increased risk for ineffective utilization of B-vitamins and potential for cell damage caused by oxidative stress, both of which can in some cases lead to increased risk for certain diseases. The test identifies the presence or absence of human genotypic markers methylenetetrahydrofolate reductase (MTHFR) and transcobalamin II (TCN2) involved in vitamin B metabolism and markers superoxide dismutase 2 (SOD2), glutathione S-transferase 1 deletions (GSTM1), paraoxonase 1 (PON1), X-ray repair cross complementing group 1 (XRCC1) in response to oxidative stress. Certain variations are associated with less efficient B-vitamin metabolism or reduced activity of endogenous anti-oxidant systems. The test may be used to aid individuals in deciding whether to supplement their diet with B vitamins and/or antioxidants.

Genetic Test Pipeline

The Company is focusing! its gene! tic test development efforts on programs, including Osteoarthritis Genetic Test. OA is the common adult joint disease, increasing in frequency and severity in all aging populations. The estimated U.S. prevalence is 20-40 million patients or five times that of rheumatoid arthritis. The Company's OA program plans to investigate whether interleukin gene variations together with several other inflammatory gene variations is associated with the occurrence of multi-joint OA for the development of a genetic risk assessment test.

Advisors' Opinion:

• [By Brian Marckx]

  Interleukin Genetics, Inc. (ILIU.PK) develops genetic tests focused on personal health. Through applied genetics research and scientific collaborations, the company has made significant progress in understanding how genetic make-up can affect an individual's predisposition and risk of suffering from certain diseases. Interleukin's research has specifically focused on a form of genetic variation called single nucleotide polymorphisms (SNP) and how it can have an impact on a person's health. The company has applied this knowledge in the development of genetic tests focused on areas such as weight management, cardiovascular health and periodontal disease. Interleukin sells its Inherent Health line of tests, which launched in 2009, to the consumer market and maintains a CLIA-certified lab at its headquarters in Waltham, Massachusetts, where consumers send test samples for processing.

Best Healthcare Equipment Companies To Watch In Right Now: pSivida Corp.(PSDV)

pSivida Corp., together with its subsidiaries, develops drug delivery products for treatment of back-of-the-eye diseases that are administered by implantation, injection, or insertion. The company?s lead product candidate includes Iluvien, which is in Phase III clinical trials and delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME), a cause of vision loss. It is also conducting Phase II clinical trials with Iluvien for the treatment of wet and dry form of age-related macular degeneration, and retinal vein occlusion. In addition, the company?s products include Retisert for the treatment of posterior uveitis, an autoimmune condition characterized by inflammation of the posterior of the eye that can cause sudden or gradual vision loss; and Vitrasert for cytomegalovirus retinitis, a blinding eye disease that occurs in individuals with advanced AIDS. It is developing the Latanoprost product, an injectable, bioerodible drug delivery implant i n Phase I/II dose-escalating study for the treatment of glaucoma and ocular hypertension; the Posterior Uveitis product candidate in a Phase I/II study for the treatment of posterior uveitis; BioSilicon technology system, which is nano-structured porous silicon designed for use as a drug delivery platform and to deliver smaller molecules; and Tethadur, which utilizes BioSilicon to deliver large biologic molecules, including peptides and proteins. It has strategic collaborations with Bausch & Lomb Incorporated; Alimera Sciences, Inc.; Pfizer, Inc.; and Intrinsiq Materials Cayman Limited. The company was founded in 1987 and is headquartered in Watertown, Massachusetts.

Advisors' Opinion:

• [By John Kell]

  Specialty pharmaceutical firm pSivida Corp.(PSDV) said the U.S. Food and Drug Administration didn’t approve a treatment for an eye disease found in patients with diabetes. The company’s stock tumbled 47% to $2 premarket, while shares of Alimera Sciences Inc.(ALIM) were down 39% to $1.66, as the treatment is licensed and sold by Alimera in other markets.

• [By Smith On Stocks]

  This note focuses on the implications of the complete response letter (CRL) received by Alimera (ALIM) for Iluvien. This product was developed by pSivida (PSDV) but was partnered with Alimera. This report deals only with the investment significance for pSivida.

Best Healthcare Equipment Companies To Watch In Right Now: ADT Corp (ADT)

The ADT Corporation (ADT), incorporated on January 18, 2012, is a provider of electronic security, interactive home and business automation, and monitoring services for residences and small businesses in the United States and Canada. The Company�� products and services include ADT Pulse interactive home and business solutions, and home health services. ADT provides business security intrusion detection, which protect the business from burglary, robbery and intruders. Its electronic access control limits unauthorized entry and employee access to the business, as well as complete access. Effective August 2, 2013, The ADT Corp acquired Devcon Security Services Corp, a provider of security protection services, from Devcon International Corp. In November 2013, Kastle Systems International announced that it had acquired Mutual Central Alarm Services and Stat-Land Security Systems from ADT Corporation.

The Company's video surveillance views events in multiple areas of facility, which has control over loss and oversees business. On October 1, 2012, the Company completed the acquisition of Absolute Security.

Advisors' Opinion:

• [By John Divine]

  Another victim of a weak earnings call, shares of security company ADT (NYSE: ADT  ) lost 6.9% after posting profits that rose just 2%. Despite adding more than 300,000 new customers, revenue failed to meet expectations, coming in at $821 million -- analysts were calling for about $824 million. While today's slide was extreme, the company isn't exactly in major trouble. It just seems to be in a phase of slow, steady growth.�

• [By Michael Robinson]

  CSD also holds shares in a stock that has prospered after being spun-off from troubled Tyco��he ADT Corp. (ADT), which is best known as a leading home security firm.

• [By Damian Illia]

  The ADT Corporation (ADT) is a provider of electronic security, interactive home and business automation and related monitoring services in the U.S. and Canada (about 6.5 million residential and small business customers).

• [By Michael Lewis]

  Home and small-business security company ADT (NYSE: ADT  ) debuted on the markets in October of last year as a spinoff of conglomerate Tyco. While spinoffs are often misunderstood or neglected investment opportunities, this one came out priced high and covered well, eliminating the opportunity for a value play. Since its IPO, the stock has only ticked up around 6% while sales and profits continue to rise. In the past quarter, the company added more than 300,000 new customers, with plenty of room to grow. It's no doubt that ADT is an industry leader, but is the stock still too expensive to warrant a buy?